Share this page:

Accel-Amplicon™ Plus Colorectal (CRC) Cancer Panel

Simultaneous detection of genes implicated in colorectal cancer.

The Accel-Amplicon Plus Colorectal Cancer Panel is an NGS multigene panel for variant discovery and screening. It combines content from peer reviewed publications and other sources to offer comprehensive and exon-level hotspot coverage of 16 clinically-relevant colorectal genes. Areas of interest include genes such as AKT1, TP53, PIK3CA, KRAS and NRAS.

Try more.  Discover more.    

The panel is modular, allowing you to add focused content to achieve your most optimal design. Either combine pre-validated content such as our Lynch Syndrome content or add your own targets.  We’ll work alongside you to design your assay and then Swift will optimize and wet-bench validate its performance before shipping it to you.

Comprehensive: Covers 11,000 COSMIC and 3,500 ClinVar mutations and generates targeted libraries compatible with Illumina® sequencing platforms. Illumina® sequencing platforms.

Informative:  Provides CNV detection of ERBB2 and full exon coverage of TP53 with flanking intron/exon boundaries.

Powerful:  Simultaneous detection of single nucleotide variants (SNV), copy number variants (CNV) and small insertions and deletions (indels), all within a fast and easy single-tube assay workflow.

Flexible:  Add our Lynch Syndrome pre-validated content or your own targets using our pre-validated primers or other content. The possibilities are endless.

Other key features include: 

  • Robust performance on cell-free DNA and FFPE samples starting with as little as 10 ngrams input.
  • Highly sensitive detection of rare variants down to 1% allele frequency.
  • Easy, single-tube assay with sequence ready libraries in under 2 hours.
  • Streamlined analysis with new bioinformatics tools including Primerclip or Genialis.
  • Compatible with all Illumina sequencers

The Accel-Amplicon workflow uses a fast, single-tube approach consisting of a 90-minute target enrichment amplification step and a 10-minute adapter ligation step, yielding a 2-hour start-to-finish procedure.

The single-tube workflow includes two brief incubations to generate the multiplex amplicon targets and add a unique combination of Illumina-compatible indexed adapters, creating up to 96 uniquely-indexed libraries for multiplexing on a single sequencing run.

Achieve Robust Sequencing Performance Over a Wide Range of Samples

 

An array of control DNA samples (10 ng input for each) was used to generate libraries with the Accel-Amplicon Plus Colorectal Cancer Panel. The samples include male and female Coriell repository DNAs of different ethnicities, Horizon HD701 quantitative multiplex reference standard, the Acrometrix™ Oncology Hotspot Control, gDNA and cfDNA extracted from human blood, circulating cell-free DNA, and three formalin-compromised samples, including Horizon HD200 FFPE. Libraries were sequenced on an Illumina MiniSeq instrument and the on target aligned reads and coverage uniformity percentages were plotted.

You may review our target BED files or gene lists to determine current content covered by our core panels. Alternatively, you may send your target list to us by completing this form and submitting to [email protected] and we will perform an intersection to determine how many new designs would be required to finalize your panel.

Core panels are available directly off the shelf and may be shipped immediately upon order. Depending on the level of customization you may wish to add to your panel, you can expect a final customized panel to be synthesized, tested, balanced, and optimized for shipment within 3-5 weeks after finalization of the design and placement of a purchase order.

Please complete this form and submit it along with the total number of samples you expect to sequence in your studies (pilot study vs. total project) to [email protected] in order to receive the most accurate and attractive pricing estimate for your customized panel.

Both open-source and commercial data analysis solutions are available. Please consult our Bioinformatics Resource page to select the best approach for your application.

The level of multiplexing is directly correlated to the size of the specific Accel-Amplicon Panel and the flow cell chemistry utilized for sequencing of the libraries. The table below provides an example of the number of libraries from the Accel-Amplicon Comprehensive TP53 and 56G Oncology Panels which can be multiplexed on a single MiSeq® flow cell. Accel-Amplicon panels currently include up to 96 indexing combinations and are consistently increasing.

*Please inquire by email to Tech Support if you require more than 96 unique indices.

Amplicon_Table_Level of Multiplexing

Lower than expected yields most likely relate to the quality and quantity of the sample, as well as how it was quantified. If possible, for severely compromised samples including FFPE, use 25 ng of qPCR-quantified input and extend the incubation time for the Indexing Step from 20 minutes to 60 minutes to improve yields. It is very important to quantify cfDNA or FFPE with qPCR as opposed to Qubit or NanoDrop to ensure there is a minimum of 10 ng of amplifiable content in the sample.

It is not recommended to use a Bioanalyzer or Qubit for quantifying libraries because there is no PCR enrichment of the library following the Indexing Step, so the Bioanalyzer or Qubit will not accurately quantify fully adapted library vs. other DNA. In addition, the Accel-Amplicon library adapters have secondary structure which exhibit migration artifacts on the Bioanalyzer.

Low cluster density is typically related to an error in library quantification. If the final library is quantified by methods other than qPCR, this will lead to determining an inaccurate value for library concentration. It is not recommended to use a Bioanalyzer or Qubit for quantifying libraries because there is no PCR enrichment of the library following the Indexing Step, so the Bioanalyzer or Qubit will not accurately quantify fully adapted library vs. other DNA.

In addition, the Accel-Amplicon library adapters have secondary structure which exhibit migration artifacts on the Bioanalyzer. When diluting the library for loading the flow cell and sequencing, if the dilution is based off an erroneous quantification the cluster density will not be optimal.

Swift is pleased to accept custom Accel-Amplicon Panel requests. We will use a custom design pipeline to generate the primer pools and provide a functionally-tested pilot kit, with pricing decided on a case-by-case basis dependent on reaction volumes and assay complexity. Please contact us by email at [email protected] and specify:

  • Number of genes to cover, with gene symbols
  • Hotspot (i.e., SNP) or whole-gene coverage requirements
  • Sample type(s) to be used with the custom panel such as FFPE, cfDNA, or high quality gDNA
  • Expected number of reactions required for the custom panel

There are multiple factors which determine the LOD, the most important being the number of copies of the variant-containing DNA actually present in the sample and the depth of sequencing performed.

There is also some variation in the reasonable LOD depending on the variant of interest. In general, the Accel-Amplicon technology is capable of a LOD down to 1% for most base substitution variants when working with 10-25 ng input DNA as quantified by a qPCR input assay.

It is very important to quantify cfDNA or FFPE with qPCR as opposed to Qubit or Nanodrop to ensure there is a minimum of 10 ng of amplifiable content in the sample for this LOD to be achieved, since for 10 ng this will be represented by ~30 mutant copies detected in ~3000 total copies.

It is also critical to achieve adequate sequencing depth to obtain sufficient mutant copy number detection. The table below illustrates observable allele frequencies for Accel-Amplicon libraries at 10 ng and 1 ng input amounts.

Please note that Swift Biosciences currently supports inputs down to 10 ng.

Amplicon_Table_Allele Frequencies

For maximal (lowest) LOD, increasing the input amount to 25 ng, if possible, will provide more confidence due to increased copy number ( > 6000 total copies and therefore > 60 copies of a 1% variant).

It is also important to note that the LOD inherent in Illumina technology can be discussed in terms of bases rated at Q30. Most bases are read with a rate of 1 error in 1000, or 0.1%. Some bases have a lower quality score and therefore the background false positive noise level is between 0.1-0.6%.

Using a base quality filter during the variant calling steps is one way to address this issue.

Swift does not currently offer a proprietary data analysis software package. Please view our technical note “Accel-Amplicon Panels: Bioinformatics Guidelines“, which includes a tutorial for using open-source Linux-based tools to perform the required primer trimming step, as well as general recommendations for the alignment and variant calling analysis.

While this can be caused by multiple factors, one of the most common explanations is that the Sample Sheet was not set to automatically trim the Illumina adapter sequences when generating the FASTQs prior to the primer trimming requirement of Accel-Amplicon Panels.

Make sure that the “Use adapter trimming” and “Use adapter trimming Read 2” are selected during the sample sheet setup. It is possible to re-run this analysis even after the sequencing run has been performed if these selections were not made during the initial sample sheet setup.

Place Order

First, select a product and quantity:

Catalog No. Description Price QTY
AP-CR8048 Accel-Amplicon™ Plus Colorectal Cancer Panel (48 rxns) $3600.00

$3,600.00Add to cart

The below solution is included with your product. If you require extra, please add now:

Catalog No. Description Price QTY
90196  PEG NaCl Solution (96 rxns) $20.00

$20.00Add to cart